our

One of our favorite Anker power banks is 41 percent off for Black Friday

I'm a big fan of Anker's chargers, especially its portable ones, as they tend to be sleek, fast and small enough to shove in my pocket (the last bit is a requirement for me). While the company's products run the gambit price-wise, there's a big sale on one of Anker's more expensive options: the 200W Prime Power Bank. Right now, you can get this power bank and its 100W charging base for just $110, down from $185 — a 41 percent discount.

Anker's 200W portable charger is our choice for best premium power bank thanks to features like charging an iPhone in an average of one hour and 48 minutes. One of the best parts of the power bank is its sleek screen, which shows the power coming in or out and how much battery the accessory is holding. This feature is much more exact than the four dots on my cheaper (but still loved) Anker Nano Power Bank

The power bank and charging base both offer one USB port and two USB-C ports so there's plenty of ways to charge your devices. The base also uses magnets to secure its pins to the power bank and charge it upright. Our biggest quip with the power bank was its high price, but with this sale it's definitely worth looking into. 

Check out all of the latest Black Friday and Cyber Monday deals here.

This article originally appeared on Engadget at https://www.engadget.com/deals/one-of-our-favorite-anker-power-banks-is-41-percent-off-for-black-friday-161543537.html?src=rss




our

Shell wins appeal in Dutch court after three-year battle against green groups

Climate activists won against Shell in 2021 when a Dutch court commanded the oil giant to reduce its carbon emissions by 45 percent by the end of 2030. Three years later, Shell managed to win its appeal against this ruling. In the court's view, Shell doesn’t have a “social standard of care” to curtail emissions, the BBC reports.

The 2021 ruling was noteworthy, as it was the first time a court made a private company obey the 2015 Paris Agreement in addition to Dutch law. However, the appeals court judge said that while Shell had an obligation to reduce emissions, a 45 percent cut could not be established as there is no universally accepted amount. Shell’s statement says it’s planning to reduce its products’ carbon intensity by a comparatively paltry 15 to 20 percent by 2030 compared to a 2016 baseline.

The 2021 ruling would only be effective in the Netherlands as well. Shell wouldn’t have been legally obligated to follow the lower court's ruling for its operations outside Dutch territory. Now even that small gain is off the table for now.

The activists, who are largely associated with Milieudefensie (the Dutch branch of Friends of the Earth), issued a statement promising to continue the fight against climate change. “Large polluters are powerful. But united, we as people have the power to change them,” said Donald Pols, Director of Milieudefensie. They’re now trying to take the case to the Supreme Court, but getting a final verdict will likely take years.

This article originally appeared on Engadget at https://www.engadget.com/science/shell-wins-appeal-in-dutch-court-after-three-year-battle-against-green-groups-165543894.html?src=rss




our

Coupe Billie Jean King: le Canada pour un improbable doublé

Leylah Fernandez et ses compatriotes auront fort à faire pour conserver leur titre.




our

Temple de la renommée: au tour de Carey Price?

Carey Price aura vraisemblablement la faveur du comité qui est appelé à décider qui sera intronisé chaque année.




our

Alan Hollinghurst explores identity and political change in his latest novel, Our Evenings

The prolific British author discussed his latest book on Bookends with Mattea Roach.




our

Noeudvembre: Régis Labeaume toujours «en mission» contre le cancer de la prostate

L’ex-maire, qui a passé cette année le cap des cinq ans depuis son diagnostic, continue de s’impliquer pour sensibiliser les hommes à ce fléau.




our

«C’était absolument nécessaire»: Laurence Jalbert a tout arrêté pendant deux mois pour guérir de la COVID

Laurence Jalbert a dû tout arrêter pendant deux mois




our

Scandale des drones: c’est terminé avec le Canada pour Bev Priestman

Canada Soccer a définitivement coupé les ponts avec la sélectionneuse de l’équipe féminine Bev Priestman.




our

Les Québécois insatisfaits de l’élection de Trump, selon un sondage Léger-Le Journal-TVA

À l’exception notable des électeurs conservateurs.




our

Procès pour triple meurtre à Brossard: incursion dans une scène de crime sanglante et chaotique pour le jury

Le jury au procès du père accusé d’avoir décimé sa famille a eu droit à une véritable incursion dans la scène de crime.




our

Sueurs froides pour deux Swifties québécoises: leurs billets volés... puis retrouvés à temps pour le concert de Taylor Swift vendredi à Toronto

Florence et Marianne seront finalement au concert de leur idole, vendredi, à Toronto, mais elles ont eu toute une frousse.




our

«Le Journal» à Toronto: aimer Taylor Swift n’a pas de prix

Des Swifties ont dépensé des centaines de dollars à la boutique de souvenirs de la vedette, à son ouverture, mardi.




our

PRIMEUR | Le PQ a choisi sa candidate pour la partielle dans Terrebonne

Le Parti Québécois misera sur sa présidente, Catherine Gentilcore, pour tenter de ravir la circonscription de Terrebonne à la CAQ.




our

Trudeau et Poilievre au coude-à-coude au Québec, selon un sondage Léger-Le Journal-TVA

Le Bloc Québécois trône toujours en tête, à 35% des intentions de vote, selon un sondage Léger-Le Journal-TVA.




our

Alberta government fires AIMCo board, four top executives, in 'reset' for pension fund manager

The province says the move comes "after years of AIMCo consistently failing to meet its mandated benchmark returns." For now, Finance Minister Nate Horner has been appointed the AIMCo board's sole director and chair. Senior public servant Ray Gilmour has been appointed interim CEO.



  • News/Canada/Edmonton

our

'Keep trying. Dream': The life and message of Murray Sinclair honoured at memorial service

The family of the late Murray Sinclair remember his life as they are joined by members of the public, the Canadian Governor General and prime minister during a commemorative service at Winnipeg's Canada Life Centre to honour his legacy Sunday afternoon.



  • News/Canada/Manitoba

our

Canada Post workers give 72-hour notice to strike as company warns of financial impact

The union representing Canada Post workers said it will be in a legal strike position on Friday, exactly one year after talks on a new contract began. But the union is holding back on deciding whether a job action will take place immediately.




our

Labour minister sends ports dispute to binding arbitration, orders end to lockouts

Labour Minister Steven MacKinnon has sent labour disputes at ports in Quebec and British Columbia to binding arbitration and has ordered people back to work after the disputes reached what he called a "total impasse."




our

Mirror tracks your wrinkles

“Magic mirror in the hand, who has the most wrinkles in the land?” has transcended from Snow White to 21st century camera technology.




our

Zach Bryan aurait offert 12 millions $ à son ex pour acheter son silence après leur rupture

Le chanteur Zach Bryan aurait demandé à son ex-copine Brianna LaPaglia de ne pas parler de leur relation en lui offrant 12 millions de dollars.




our

Le film «Monsieur Aznavour» présenté à Montréal samedi: une première «symbolique» pour le réalisateur Grand Corps Malade

Gros succès en France, le drame biographique est présenté samedi au Festival Cinemania.




our

Des Swifties québécois témoignent: «En spectacle, le monde arrête de tourner»

Des Swifties québécoises racontent leur expérience durant un concert de la tournée «Eras».




our

Le Canadien, un vrai désastre pour tout le Québec et la télé

Geoff Molson, Kent Hughes et Martin St-Louis avaient promis que le Canadien de Montréal serait dans le «mix» cette saison.




our

Humour: un premier spectacle solo pour Patrice L’Ecuyer

Un premier spectacle d’humour en solo, intitulé «Après seulement 32 ans d’absence sur scène».




our

Karol G s’excuse pour des paroles jugées offensantes dans son nouveau single

La vedette colombienne du reggaeton Karol G s’est excusée pour des paroles de son nouveau single «+57» jugées offensantes.




our

Toboggan 2024: La Bottine Souriante et MATTN défonceront l’année à Québec

La ville de Québec pourra compter sur des prestations du groupe La Bottine Souriante et de la DJ belge MATTN pour l’amener en 2025.




our

Les White Stripes abandonnent les poursuites judiciaires contre Donald Trump

Les White Stripes ont abandonné leur plainte sur les droits d'auteur contre le président des États-Unis nouvellement réélu, Donald Trump.




our

«Le Journal» à Toronto: la Ville Reine prête pour Taylor Swift

Les signes de l’arrivée imminente de la vedette et sa tournée «Eras» sont nombreux dans la métropole canadienne.




our

Holiday in Greenland? New airports aim to entice tourists

The Arctic territory hopes that three new airports will pave the way for direct flights from the US and Europe.




our

Why Canada wants more overseas tourists to visit

Canada has launched a tourist drive but will tensions with China doom it to fail?




our

Être actif pour prévenir le cancer du pancréas

Selon une étude, l’activité physique régulière pourrait atténuer le risque de développer un cancer du pancréas, qui touche les personnes obèses.




our

Pour le risque de cancer, l’obésité santé, ça n’existe pas!

Une étude récente confirme que les personnes obèses, même sans anomalies métaboliques, sont à plus haut risque de plusieurs types de cancer.




our

National online certificate course for pathologists on cervical cancer screening to begin from November 25

The Indian Council of Medical Research─National Institute of Cancer Prevention and Research (ICMR─NICPR) is set to launch its first─ever DHR─funded National NICPR─ECHO online certificate course on cervical




our

The Universe in 100 Colors Provides a Stunning Tour through Science

A science photo book probes the colors we can see—and even “forbidden” colors we can’t




our

Does the Coriolis Effect Cause Your Cowlick?

No, but the direction of our hair whorls could teach us about human development




our

How to Make Your Own Zoetrope

Put your own spin on a zoetrope with homemade drawings—or carve one into a pumpkin




our

The Climate and the Health of our Children Is on the Ballot on November 5

The 2024 presidential election will have enormous consequences for the climate, and the health and future of children




our

How to Calm Your Election Anxiety—Even after Polls Close

People are really stressed about the U.S. presidential election. A psychiatrist offers several self-help methods to reduce feelings of despair




our

Consciousness Might Hide in Our Brain’s Electric Fields

A mysterious electromagnetic mechanism may be more important than the firing of neurons in our brain to explain our awareness




our

The Lucy Fossil’s Extraordinary Journey to Becoming an Icon of Human Evolution

The 3.2-million-year-old human ancestor known as Lucy rose to fame through an incredible combination of circumstances




our

ACRO Announces Diversity and Inclusion Site Resource Grants Program

The ACRO D&I Site Resource Grants Program aims to help sites acquire the resources and skills that will get them selected for studies and improve the reach of clinical research into underrepresented communities.

The post ACRO Announces Diversity and Inclusion Site Resource Grants Program first appeared on ACRO.




our

ACRO Announces Diversity and Inclusion Site Resource Grants Program

ACRO is pleased to announce the launch of the ACRO Diversity and Inclusion Site Resource Grants Program! The ACRO D&I Site Resource Grants Program aims to help sites acquire the resources and skills that will get them selected for studies and improve the reach of clinical research into underrepresented communities. “We are excited to invite […]

The post ACRO Announces Diversity and Inclusion Site Resource Grants Program first appeared on ACRO.




our

Off-Label Promotion: Best Resolved by Congress, Not Courts

On December 3, a federal appeals court ruled against one of the FDA’s untouchable restrictions on industry—thou shalt not promote the off-label use of pharmaceutical products. An industry that is little interested in constitutional law suddenly finds itself talking about the First Amendment and whether, and on what grounds, the case will be appealed. Meantime, the court’s decision left FDA Matters torn between cheering and booing. Patients are poorly served if their doctor is prescribing drugs without being able to tap into all sources of relevant knowledge. However, permitting off-label promotion undercuts the incentive for companies to thoroughly investigate the safety and efficacy of a drug for a second or third use.



  • Drug Approval and Access
  • FDA and Congress
  • FDA and Industry
  • Insight on FDA-regulated Industries

our

Massachusetts High Court Rules Online Tracking Doesn’t Violate State Wiretap Law

Sorry, but you do not have permission to view this content.



  • Courts/First Amendment

our

Can a Form Letter from FDA "Blow Your Mind"?

Adam Feuerstein appears to be a generally astute observer of the biotech scene. As a finance writer, he's accosted daily with egregiously hyped claims from small drug companies and their investors, and I think he tends to do an excellent job of spotting cases where breathless excitement is unaccompanied by substantive information.


However, Feuerstein's healthy skepticism seems to have abandoned him last year in the case of a biotech called Sarepta Therapeutics, who released some highly promising - but also incredibly limited - data on their treatment for Duchenne muscular dystrophy. After a disappointing interaction with the FDA, Sarepta's stock dropped, and Feuerstein appeared to realize that he'd lost some objectivity on the topic.


However, with the new year comes new optimism, and Feuerstein seems to be back to squinting hard at tea leaves - this time in the case of a form letter from the FDA.


He claims that the contents of the letter will "blow your mind". To him, the key passage is:


We understand that you feel that eteplirsen is highly effective, and may be confused by what you have read or heard about FDA's actions on eteplirsen. Unfortunately, the information reported in the press or discussed in blogs does not necessarily reflect FDA's position. FDA has reached no conclusions about the possibility of using accelerated approval for any new drug for the treatment of Duchenne muscular dystrophy, and for eteplirsen in particular.


Feuerstein appears to think that the fact that FDA "has reached no conclusions" may mean that it may be "changing its mind". To which he adds: "Wow!"
Adam Feuerstein: This time,
too much froth, not enough coffee?


I'm not sure why he thinks that. As far as I can tell, the FDA will never reach a conclusion like this before its gone through the actual review process. After all, if FDA already knows the answer before the full review, what would the point of the review even be? It would seem a tremendous waste of agency resources. Not to mention how non-level the playing field would be if some companies were given early yes/no decisions while others had to go through a full review.


It seems fair to ask: is this a substantive change by FDA review teams, or would it be their standard response to any speculation about whether and how they would approve or reject a new drug submission? Can Feuerstein point to other cases where FDA has given a definitive yes or no on an application before the application was ever filed? I suspect not, but am open to seeing examples.


A more plausible theory for this letter is that the FDA is attempting a bit of damage control. It is not permitted to share anything specific it said or wrote to Sarepta about the drug, and has come under some serious criticism for “rejecting” Sarepta’s Accelerated Approval submission. The agency has been sensitive to the DMD community, even going so far as to have Janet Woodcock and Bob Temple meet with DMD parents and advocates last February. Sarepta has effectively positioned FDA as the reason for it’s delay in approval, but no letters have actually been published, so the conversation has been a bit one-sided. This letter appears to be an attempt at balancing perspectives a bit, although the FDA is still hamstrung by its restriction on relating any specific communications.

Ultimately, this is a form letter that contains no new information: FDA has reached no conclusions because FDA is not permitted to reach conclusions until it has completed a fair and thorough review, which won't happen until the drug is actually submitted for approval.

We talk about "transparency" in terms of releasing clinical trials data, but to me there is a great case to be made for increase regulatory transparency. The benefits to routine publication of most FDA correspondence and meeting results (including such things as Complete Response letters, explaining FDA's thinking when it rejects new applications) would actually go a long way towards improving public understanding of the drug review and approval process.




our

Patient Centered Trials - Your Thoughts Needed

The good folks down at eyeforpharma have asked me to write a few blog posts in the run-up to their Patient Centered Clinical Trials conference in Boston this September. In my second article -Buzzword Innovation: The Patient Centricity “Fad” and the Token Patient - I went over some concerns I have regarding the sudden burst of enthusiasm for patient centricity in the clinical trial world.

Apparently, that hit a nerve – in an email, Ulrich Neumann tells me that “your last post elicited quite a few responses in my inbox (varied, some denouncing it as a fad, others strongly protesting the notion, hailing it as the future).”

In preparing my follow up post, I’ve spoken to a couple people on the leading edge of patient engagement:


In addition to their thoughts, eyeforpharma is keenly interested in hearing from more people. They've even posted a survey – from Ulrich:
To get a better idea of what other folks think of the idea, I am sending out a little ad hoc survey. Only 4 questions (so people hopefully do it). Added benefit: There is a massive 50% one-time discount for completed surveys until Friday connected to it as an incentive).
So, here are two things for you to do:

  1. Complete the survey and share your thoughts
  2. Come to the conference and tell us all exactly what you think

Look forward to seeing you there.

[Conflict of Interest Disclosure: I am attending the Patient Centered Clinical Trials conference. Having everyone saying the same thing at such conferences conflicts with my ability to find them interesting.]





our

Will Your Family Make You a Better Trial Participant?

It is becoming increasing accepted within the research community that patient engagement leads to a host of positive outcomes – most importantly (at least practically speaking) improved clinical trial recruitment and retention.

But while we can all agree that "patient engagement is good" in a highly general sense, we don't have much consensus on what the implications of that idea might be. There is precious little hard evidence about how to either attract engaged patients, or how we might effectively turn "regular patients" into "engaged patients".

That latter point - that we could improve trial enrollment and completion rates by converting the (very large) pool of less-engaged patient - is a central tenet of the mHealth movement in clinical trials. Since technology can now accompany us almost anywhere, it would seem that we have an unprecedented opportunity to reach out and connect with current and potential trial participants.

However, there are signs that this promised revolution in patient engagement hasn't come about. From the decline of new apps being downloaded to the startlingly high rate of people abandoning their wearable health devices, there's a growing body of evidence suggesting that we aren't in fact making very good progress towards increasing engagement. We appear to have underestimated the inertia of the disengaged patient.

So what can we do? We know people like their technology, but if they're not using it to engage with their healthcare decisions, we're no better off as a result.

Daniel Calvert, in a recent blog post at Parallel 6 offers an intriguing solution: he suggests we go beyond the patient and engage their wider group of loved ones. By engaging what Calvert calls the Support Circle - those people most likely to "encourage the health and well being of that patient as they undergo a difficult period of their life" - trial teams will find themselves with a more supported, and therefore more engaged, participant, with corresponding benefits to enrollment and retention. 

Calvert outlines a number of potential mechanisms to get spouses, children, and other loved ones involved in the trial process:
During the consent process the patient can invite their support team in with them. A mobile application can be put on their phones enabling encouraging messages, emails, and texts to be sent. Loved ones can see if their companion or family member did indeed take today’s medication or make last Monday’s appointment. Gamification offers badges or pop-ups: “Two months of consecutive appointments attended” or “perfect eDiary log!” Loved ones can see those notifications, like/comment, and constantly encourage the patients. 
Supporting materials can also be included in the Support Circle application. There are a host of unknown terms to patients and their team. Glossaries, videos, FAQs, contact now, and so much more can be made available at their fingertips.
I have to admit I'm fascinated by Calvert's idea. I want him to be right: the picture of supportive, encouraging, loving spouses and children standing by to help a patient get through a clinical trial is an attractive one. So is the idea that they're just waiting for us to include them - all we need to do is a bit of digital communication with them to get them fully on board as members of the study team.

The problem, however, remains: we have absolutely no evidence that this approach will work. There is no data showing that it is superior to other approaches to engage trial patients.

(In fact, we may even have some indirect evidence that it may hinder enrollment: in trials that require active caregiver participation, such as those in Alzheimer's Disease, caregivers are believed to often contribute to the barriers to patient enrollment).

Calvert's idea is a good one, and it's worthy of consideration. More importantly, it's worthy of being rigorously tested against other recruitment and retention approaches. We have a lot of cool new technologies, and even more great ideas - we're not lacking for those. What we're lacking is hard data showing us how these things perform. What we especially need is comparative data showing how new tactics work relative to other approaches.

Over 5 years ago, I wrote a blog post bemoaning the sloppy approaches we take in trial recruitment - a fact made all the more painfully ironic by the massive intellectual rigor of the trials themselves. I'm not at all sure that we've made any real progress in those 5 years.

In my next post, I'll outline what I believe are some of the critical steps we need to take to improve the current situation, and start bringing some solid evidence to the table along with our ideas.

[Photo credit: Flikr user Matthew G, "Love (of technology)"]







our

For good sleep and good health, regulate your exposure to light

Your daily light exposure impacts your health. A new study finds that too much light at night and not enough natural light during the day can be harmful. This story first aired on Morning Edition on Nov. 4, 2024.




our

Patrick Dempsey aims to raise awareness of cancer disparities and encourage screening

NPR's Leila Fadel talks with actor Patrick Dempsey about his efforts to raise money for cancer treatment and prevention.




our

Apps Put a Psychiatrist in Your Pocket



Nearly every day since she was a child, Alex Leow, a psychiatrist and computer scientist at the University of Illinois Chicago, has played the piano. Some days she plays well, and other days her tempo lags and her fingers hit the wrong keys. Over the years, she noticed a pattern: How well she plays depends on her mood. A bad mood or lack of sleep almost always leads to sluggish, mistake-prone music.

In 2015, Leow realized that a similar pattern might be true for typing. She wondered if she could help people with psychiatric conditions track their moods by collecting data about their typing style from their phones. She decided to turn her idea into an app.

After conducting a pilot study, in 2018 Leow launched BiAffect, a research app that aims to understand mood-related symptoms of bipolar disorder through keyboard dynamics and sensor data from users’ smartphones. Now in use by more than 2,700 people who have volunteered their data to the project, the app tracks typing speed and accuracy by swapping the phone’s onscreen keyboard with its own nearly identical one.

The software then generates feedback for users, such as a graph displaying hourly keyboard activity. Researchers get access to the donated data from users’ phones, which they use to develop and test machine learning algorithms that interpret data for clinical use. One of the things Leow’s team has observed: When people are manic—a state of being overly excited that accompanies bipolar disorder—they type “ferociously fast,” says Leow.

Compared to a healthy user [top], a person experiencing symptoms of bipolar disorder [middle] or depression [bottom] may use their phone more than usual and late at night. BiAffect measures phone usage and orientation to help track those symptoms. BiAffect

BiAffect is one of the few mental-health apps that take a passive approach to collecting data from a phone to make inferences about users’ mental states. (Leow suspects that fewer than a dozen are currently available to consumers.) These apps run in the background on smartphones, collecting different sets of data not only on typing but also on the user’s movements, screen time, call and text frequency, and GPS location to monitor social activity and sleep patterns. If an app detects an abrupt change in behavior, indicating a potentially hazardous shift in mental state, it could be set up to alert the user, a caretaker, or a physician.

Such apps can’t legally claim to treat or diagnose disease, at least in the United States. Nevertheless, many researchers and people with mental illness have been using them as tools to track signs of depression, schizophrenia, anxiety, and bipolar disorder. “There’s tremendous, immediate clinical value in helping people feel better today by integrating these signals into mental-health care,” says John Torous, director of digital psychiatry at Beth Israel Deaconess Medical Center, in Boston. Globally, one in 8 people live with a mental illness, including 40 million with bipolar disorder.

These apps differ from most of the more than 10,000 mental-health and mood apps available, which typically ask users to actively log how they’re feeling, help users connect to providers, or encourage mindfulness. The popular apps Daylio and Moodnotes, for example, require journaling or rating symptoms. This approach requires more of the user’s time and may make these apps less appealing for long-term use. A 2019 study found that among 22 mood-tracking apps, the median user-retention rate was just 6.1 percent at 30 days of use.

App developers are trying to avoid the pitfalls of previous smartphone-psychiatry startups, some of which oversold their capabilities before validating their technologies.

But despite years of research on passive mental-health apps, their success is far from guaranteed. App developers are trying to avoid the pitfalls of previous smartphone psychiatry startups, some of which oversold their capabilities before validating their technologies. For example, Mindstrong was an early startup with an app that tracked taps, swipes, and keystrokes to identify digital biomarkers of cognitive function. The company raised US $160 million in funding from investors, including $100 million in 2020 alone, and went bankrupt in February 2023.

Mindstrong may have folded because the company was operating on a different timeline from the research, according to an analysis by the health-care news website Stat. The slow, methodical pace of science did not match the startup’s need to return profits to its investors quickly, the report found. Mindstrong also struggled to figure out the marketplace and find enough customers willing to pay for the service. “We were first out of the blocks trying to figure this out,” says Thomas Insel, a psychiatrist who cofounded Mindstrong.

Now that the field has completed a “hype cycle,” Torous says, app developers are focused on conducting the research needed to prove their apps can actually help people. “We’re beginning to put the burden of proof more on those developers and startups, as well as academic teams,” he says. Passive mental-health apps need to prove they can reliably parse the data they’re collecting, while also addressing serious privacy concerns.

Passive sensing catches mood swings early

Mood Sensors

Seven metrics apps use to make inferences about your mood

All icons: Greg Mably

Keyboard dynamics: Typing speed and accuracy can indicate a lot about a person’s mood. For example, people who are manic often type extremely fast.

Accelerometer: This sensor tracks how the user is oriented and moving. Lying in bed would suggest a different mood than going for a run.

Calls and texts: The frequency of text messages and phone conversations signifies a person’s social isolation or activity, which indicates a certain mood.

GPS location: Travel habits signal a person’s activity level and routine, which offer clues about mood. For example, a person experiencing depression may spend more time at home.

Mic and voice: Mood can affect how a person speaks. Microphone-based sensing tracks the rhythm and inflection of a person’s voice.

Sleep: Changes in sleep patterns signify a change in mood. Insomnia is a common symptom of bipolar disorder and can trigger or worsen mood disturbances.

Screen time: An increase in the amount of time a person spends on a phone can be a sign of depressive symptoms and can interfere with sleep.

A crucial component of managing psychiatric illness is tracking changes in mental states that can lead to more severe episodes of the disease. Bipolar disorder, for example, causes intense swings in mood, from extreme highs during periods of mania to extreme lows during periods of depression. Between 30 and 50 percent of people with bipolar disorder will attempt suicide at least once in their lives. Catching early signs of a mood swing can enable people to take countermeasures or seek help before things get bad.

But detecting those changes early is hard, especially for people with mental illness. Observations by other people, such as family members, can be subjective, and doctor and counselor sessions are too infrequent.

That’s where apps come in. Algorithms can be trained to spot subtle deviations from a person’s normal routine that might indicate a change in mood—an objective measure based on data, like a diabetic tracking blood sugar. “The ability to think objectively about my own thinking is really key,” says retired U.S. major general Gregg Martin, who has bipolar disorder and is an advisor for BiAffect.

The data from passive sensing apps could also be useful to doctors who want to see objective data on their patients in between office visits, or for people transitioning from inpatient to outpatient settings. These apps are “providing a service that doesn’t exist,” says Colin Depp, a clinical psychologist and professor at the University of California, San Diego. Providers can’t observe their patients around the clock, he says, but smartphone data can help close the gap.

Depp and his team have developed an app that uses GPS data and microphone-based sensing to determine the frequency of conversations and make inferences about a person’s social interactions and isolation. The app also tracks “location entropy,” a metric of how much a user moves around outside of routine locations. When someone is depressed and mostly stays home, location entropy decreases.

Depp’s team initially developed the app, called CBT2go, as a way to test the effectiveness of cognitive behavioral therapy in between therapy sessions. The app can now intervene in real time with people experiencing depressive or psychotic symptoms. This feature helps people identify when they feel lonely or agitated so they can apply coping skills they’ve learned in therapy. “When people walk out of the therapist’s office or log off, then they kind of forget all that,” Depp says.

Another passive mental-health-app developer, Ellipsis Health in San Francisco, uses software that takes voice samples collected during telehealth calls to gauge a person’s level of depression, anxiety, and stress symptoms. For each set of symptoms, deep-learning models analyze the person’s words, rhythms, and inflections to generate a score. The scores indicate the severity of the person’s mental distress, and are based on the same scales used in standard clinical evaluations, says Michael Aratow, cofounder and chief medical officer at Ellipsis.

Aratow says the software works for people of all demographics, without needing to first capture baseline measures of an individual’s voice and speech patterns. “We’ve trained the models in the most difficult use cases,” he says. The company offers its platform, including an app for collecting the voice data, through health-care providers, health systems, and employers; it’s not directly available to consumers.

In the case of BiAffect, the app can be downloaded for free by the public. Leow and her team are using the app as a research tool in clinical trials sponsored by the U.S. National Institutes of Health. These studies aim to validate whether the app can reliably monitor mood disorders, and determine whether it could also track suicide risk in menstruating women and cognition in people with multiple sclerosis.

BiAffect’s software tracks behaviors like hitting the backspace key frequently, which suggests more errors, and an increase in typing “@” symbols and hashtags, which suggest more social media use. The app combines this typing data with information from the phone’s accelerometer to determine how the user is oriented and moving—for example, whether the user is likely lying down in bed—which yields more clues about mood.

Ellipsis Health analyzes audio captured during telehealth visits to assign scores for depression, anxiety, and stress.Ellipsis Health

The makers of BiAffect and Ellipsis Health don’t claim their apps can treat or diagnose disease. If app developers want to make those claims and sell their product in the United States, they would first have to get regulatory approval from the U.S. Food and Drug Administration. Getting that approval requires rigorous and large-scale clinical trials that most app makers don’t have the resources to conduct.

Digital-health software depends on quality clinical data

The sensing techniques upon which passive apps rely—measuring typing dynamics, movement, voice acoustics, and the like—are well established. But the algorithms used to analyze the data collected by the sensors are still being honed and validated. That process will require considerably more high-quality research among real patient populations.

Greg Mably

For example, clinical studies that include control or placebo groups are crucial and have been lacking in the past. Without control groups, companies can say their technology is effective “compared to nothing,” says Torous at Beth Israel.

Torous and his team aim to build software that is backed by this kind of quality evidence. With participants’ consent, their app, called mindLAMP, passively collects data from their screen time and their phone’s GPS and accelerometer for research use. It’s also customizable for different diseases, including schizophrenia and bipolar disorder. “It’s a great starting point. But to bring it into the medical context, there’s a lot of important steps that we’re now in the middle of,” says Torous. Those steps include conducting clinical trials with control groups and testing the technology in different patient populations, he says.

How the data is collected can make a big difference in the quality of the research. For example, the rate of sampling—how often a data point is collected—matters and must be calibrated for the behavior being studied. What’s more, data pulled from real-world environments tends to be “dirty,” with inaccuracies collected by faulty sensors or inconsistencies in how phone sensors initially process data. It takes more work to make sense of this data, says Casey Bennett, an assistant professor and chair of health informatics at DePaul University, in Chicago, who uses BiAffect data in his research.

One approach to addressing errors is to integrate multiple sources of data to fill in the gaps—like combining accelerometer and typing data. In another approach, the BiAffect team is working to correlate real-world information with cleaner lab data collected in a controlled environment where researchers can more easily tell when errors are introduced.

Who participates in the studies matters too. If participants are limited to a particular geographic area or demographic, it’s unclear whether the results can be applied to the broader population. For example, a night-shift worker will have different activity patterns from those with nine-to-five jobs, and a city dweller may have a different lifestyle from residents of rural areas.

After the research is done, app developers must figure out a way to integrate their products into real-world medical contexts. One looming question is when and how to intervene when a change in mood is detected. These apps should always be used in concert with a professional and not as a replacement for one, says Torous. Otherwise, the app’s assessments could be dangerous and distressing to users, he says.

When mood tracking feels like surveillance

No matter how well these passive mood-tracking apps work, gaining trust from potential users may be the biggest stumbling block. Mood tracking could easily feel like surveillance. That’s particularly true for people with bipolar or psychotic disorders, where paranoia is part of the illness.

Keris Myrick, a mental-health advocate, says she finds passive mental-health apps “both cool and creepy.” Myrick, who is vice president of partnerships and innovation at the mental-health-advocacy organization Inseparable, has used a range of apps to support her mental health as a person with schizophrenia. But when she tested one passive sensing app, she opted to use a dummy phone. “I didn’t feel safe with an app company having access to all of that information on my personal phone,” Myrick says. While she was curious to see if her subjective experience matched the app’s objective measurements, the creepiness factor prevented her from using the app enough to find out.

Keris Myrick, a mental-health advocate, says she finds passive mental-health apps “both cool and creepy.”

Beyond users’ perception, maintaining true digital privacy is crucial. “Digital footprints are pretty sticky these days,” says Katie Shilton, an associate professor at the University of Maryland focused on social-data science. It’s important to be transparent about who has access to personal information and what they can do with it, she says.

“Once a diagnosis is established, once you are labeled as something, that can affect algorithms in other places in your life,” Shilton says. She cites the misuse of personal data in the Cambridge Analytica scandal, in which the consulting firm collected information from Facebook to target political advertising. Without strong privacy policies, companies producing mental-health apps could similarly sell user data—and they may be particularly motivated to do so if an app is free to use.

Conversations about regulating mental-health apps have been ongoing for over a decade, but a Wild West–style lack of regulation persists in the United States, says Bennett of DePaul University. For example, there aren’t yet protections in place to keep insurance companies or employers from penalizing users based on data collected. “If there aren’t legal protections, somebody is going to take this technology and use it for nefarious purposes,” he says.

Some of these concerns may be mediated by confining all the analysis to a user’s phone, rather than collecting data in a central repository. But decisions about privacy policies and data structures are still up to individual app developers.

Leow and the BiAffect team are currently working on a new internal version of their app that incorporates natural-language processing and generative AI extensions to analyze users’ speech. The team is considering commercializing this new version in the future, but only following extensive work with industry partners to ensure strict privacy safeguards are in place. “I really see this as something that people could eventually use,” Leow says. But she acknowledges that researchers’ goals don’t always align with the desires of the people who might use these tools. “It is so important to think about what the users actually want.”

This article appears in the July 2024 print issue as “The Shrink in Your Pocket.”